These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2412936)

  • 21. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy.
    Luef G; Abraham I; Hoppichler F; Trinka E; Unterberger I; Bauer G; Lechleitner M
    Metabolism; 2002 Oct; 51(10):1274-8. PubMed ID: 12370846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Valproate metabolites in high-dose valproate plus phenytoin therapy.
    Sugimoto T; Muro H; Woo M; Nishida N; Murakami K
    Epilepsia; 1996 Dec; 37(12):1200-3. PubMed ID: 8956852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Derivation and evaluation of an equation for prediction of free phenytoin concentration in patients co-medicated with valproic acid.
    Haidukewych D; Rodin EA; Zielinski JJ
    Ther Drug Monit; 1989; 11(2):134-9. PubMed ID: 2497562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood ammonia level during valproic acid therapy.
    Kugoh T; Yamamoto M; Hosokawa K
    Jpn J Psychiatry Neurol; 1986 Dec; 40(4):663-8. PubMed ID: 3110472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein binding of valproic acid in Japanese pediatric and adult patients with epilepsy.
    Kodama Y; Kodama H; Kuranari M; Tsutsumi K; Ono S; Yamaguchi T; Fujimura A
    Am J Health Syst Pharm; 2002 May; 59(9):835-40. PubMed ID: 12004461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug interaction between phenytoin and valproic acid in a child with refractory epilepsy: a case report.
    Carvalho IV; Carnevale RC; Visacri MB; Mazzola PG; de Fátima Lopes Ambrósio R; dos Reis MC; de Queiroz RA; Moriel P
    J Pharm Pract; 2014 Apr; 27(2):214-6. PubMed ID: 24381240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of single doses of sodium valproate on serum phenytoin levels and protein binding in epileptic patients.
    Monks A; Richens A
    Clin Pharmacol Ther; 1980 Jan; 27(1):89-95. PubMed ID: 6985856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic valproic acid therapy and incidence of increases in venous plasma ammonia.
    Haidukewych D; John G; Zielinski JJ; Rodin EA
    Ther Drug Monit; 1985; 7(3):290-4. PubMed ID: 3931312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of chronic carbamazepine, valproic acid and phenytoin medication on the periodontal condition of epileptic children and adolescents.
    Galas-Zgorzalewicz B; Borysewicz-Lewicka M; Zgorzalewicz M; Borowicz-Andrzejewska E
    Funct Neurol; 1996; 11(4):187-93. PubMed ID: 8934150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of sodium valproate and phenytoin as single drug treatment in epilepsy.
    Shakir RA; Johnson RH; Lambie DG; Melville ID; Nanda RN
    Epilepsia; 1981 Feb; 22(1):27-33. PubMed ID: 6781888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolonged use of phenytoin, carbamazepine or valproate monotherapy on plasma levels of folate and B(12): a comparison between epileptic patients with or without cardiovascular disorders.
    Otoom S; Bakhiet M; Khan A; Sequeira R
    Neuro Endocrinol Lett; 2006; 27(1-2):85-8. PubMed ID: 16648782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epileptic patients refractory to drug therapy.
    Paris L; Giardina M; Pacifici R; Pichini S; Zuccaro P; Sideri G
    Ital J Neurol Sci; 1991 Oct; 12(5):447-51. PubMed ID: 1955301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of associated antiepileptic treatment on valproate-induced hyperammonemia.
    Zaccara G; Paganini M; Campostrini R; Moroni F; Valenza T; Messori A; Bartelli M; Arnetoli G; Zappoli R
    Ther Drug Monit; 1985; 7(2):185-90. PubMed ID: 3927530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum copper and zinc levels in epileptic children with valproate treatment.
    Kaji M; Ito M; Okuno T; Momoi T; Sasaki H; Yamanaka C; Yorifuji T; Mikawa H
    Epilepsia; 1992; 33(3):555-7. PubMed ID: 1592036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A correlation between the levels of phenobarbital, phenytoin and valproic acid in the blood serum and in saliva from children treated due to epilepsy.
    Sobaniec W
    Mater Med Pol; 1989; 21(4):323-6. PubMed ID: 2489248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum bilirubin levels with antiepileptic drugs.
    Gough H; Goggin T; Crowley M; Callaghan N
    Epilepsia; 1989; 30(5):597-602. PubMed ID: 2507305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of valproate and topiramate use on serum insulin, leptin, neuropeptide Y and ghrelin levels in epileptic children.
    Çiçek NP; Kamaşak T; Serin M; Okten A; Alver A; Cansu A
    Seizure; 2018 May; 58():90-95. PubMed ID: 29679911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is free fraction measurement of phenytoin always necessary in pediatric epileptic patients?
    Johno I; Kuzuya T; Suzuki K; Hasegawa M; Nakamura T; Kitazawa S; Aso K; Watanabe K
    Ther Drug Monit; 1988; 10(1):39-44. PubMed ID: 3376180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time-dependent interaction between phenytoin and valproic acid.
    Riva R; Albani F; Contin M; Perucca E; Ambrosetto G; Gobbi G; Santucci M; Procaccianti G; Baruzzi A
    Neurology; 1985 Apr; 35(4):510-5. PubMed ID: 3920548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors for hyperammonemia in pediatric patients with epilepsy.
    Yamamoto Y; Takahashi Y; Imai K; Mishima N; Yazawa R; Inoue K; Itoh K; Kagawa Y; Inoue Y
    Epilepsia; 2013 Jun; 54(6):983-9. PubMed ID: 23409971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.